Takeda Pharmaceutical (TAK) has received approval from Japan's Ministry of Health, Labour and Welfare for Orzeyful to treat narcolepsy type 1 in adults, the company said Monday.
The approval was supported by data including phase 3 results showing the drug delivers statistically significant improvements in disease symptoms, Takeda said.
The company expects to launch the product as quickly as possible.
The drug has received similar approvals in US and China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.